Johnson & Johnson (JNJ) Reports Positive Phase 3 Study Results f

Johnson & Johnson (JNJ) Reports Positive Phase 2 Study Results

Johnson & Johnson (JNJ) Reports Promising Trial Results for Amiv

J&J seeks expanded use for drug after positive head and neck cancer study (JNJ:NYSE)

Johnson & Johnson (JNJ) Reports Promising Results for Prostate C

J&J study suggests earlier use of prostate cancer drug improves outcomes (JNJ:NYSE)

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long…

New J&J drug combo delays extra prostate cancer treatment by years

MUFG Securities EMEA plc Purchases 195,912 Shares of Johnson & Johnson $JNJ

New cancer jab returns ‘unprecedented’ results in major clinical trial

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 17,914 Shares of Johnson & Johnson $JNJ

Why Johnson & Johnson might be the smartest dividend king to buy in today's market

Cancer jab can eradicate entire tumours in patients, trial shows

ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win